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We examined the expression of the midkine (MK) and a-fetoprotein (AFP) genes in 15 paired human specimens obtained from
hepatocellular carcinoma (HCC) and the corresponding noncancerous regions of the same patients. A total of 14 HCC but none of
the noncancerous specimens were positive for the MK mRNA. In contrast, three HCC specimens and one corresponding
noncancerous sample out of the three AFP-positive HCC cases expressed the AFP gene. A 2.3-kb genomic fragment in the regulatory
region of the MK gene could activate a fused reporter gene in both AFP-producing and -nonproducing HCC lines, and the MK
fragment-mediated transcriptional activity was comparable to the AFP enhancer-linked AFP promoter in AFP-producing cell lines.
The AFP-producing but not AFP-nonproducing HCC cell lines that were transfected with the MK promoter-linked herpes simplex
virus-thymidine kinase (HSV-TK) gene became susceptible to a prodrug ganciclovir to a similar degree of the HCC transfected with the
enhancer-linked AFP promoter-fused HSV-TK gene. These data suggest that the MK promoter can activate a therapeutic gene
preferentially in HCC and is as useful as the AFP promoter in clinical settings.
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Preferential expression of a cytotoxic gene in tumours is a
therapeutic approach to cancer treatment. Regulatory sequences of
the gene that is expressed primarily in tumours can activate a
fused exogenous gene in the tumours and the use of such promoter
regions has been investigated for its clinical feasibility (Miller and
Whelan, 1997). Regulated expression of a suicide gene with the
promoters can primarily destroy tumour cells and leave the
surrounding tissues undamaged. The a-fetoprotein promoter
(AFP) is a representative one to activate an exogenous gene
specifically in hepatocellular carcinoma (HCC) (Tamaoki, 2000)
and has been applied to targeted gene therapy for HCC (Kanai et al,
1996; Mawatari et al, 1998; Hallenbeck et al, 1999). Precise analysis
of the regulatory region of the AFP gene demonstrated that
enhancer and silencer elements in the region played a crucial role
in the transcription (Nakabayashi et al, 1991) and the silencer-
deleted, enhancer-linked AFP promoter showed noticeable ther-
apeutic effects compared with the unmodified AFP promoter
(Mawatari et al, 1998).
Midkine (MK) is a heparin-binding growth factor (Kadomatsu
et al, 1988) with a number of functions: forced expression of MK
induced transformation (Kadomatsu et al, 1997) and elevated
angiogenesis (Choudhuri et al, 1997). Expression of the MK gene
in human adult tissues is extremely low and restricted; however,
the expression is upregulated in a number of human tumours
particularly in gastrointestinal tumours including HCC (Aridome
et al, 1995; Koide et al, 1999). The 50 upstream region of the MK
gene was demonstrated to activate a suicide gene in MK-positive
human tumours (Adachi et al, 2000; Miyauchi et al, 2001;
Wesseling et al, 2001). In this study, we compared the usefulness
of the AFP and the MK promoters for HCC treatment by
examining the frequency of MK and AFP expression in human
HCC specimens and the transcriptional activity of the promoters
in HCC cell lines.
MATERIALS AND METHODS
Tissue samples and cells
Paired cancerous and noncancerous specimens obtained from the
same HCC patients were provided by the Chiba Cancer Center
Tissue Bank. The clinical data regarding respective patients were Received 24 December 2002; revised 5 June 2003; accepted 8 July 2003
*Correspondence: Dr M Tagawa;
E-mail: mtagawa@chiba-ccri.chuo.chiba.jp
8These authors contributed equally to this work.
British Journal of Cancer (2003) 89, 1086–1090
& 2003 Cancer Research UK All rights reserved 0007– 0920/03 $25.00
www.bjcancer.com
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
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genome study and genetic analysis (issued by the Japanese
government in 2001). Histological types of HCC were determined
according to the classification of the Liver Cancer Study Group of
Japan. Human HCC cells (HuH-7, PLC/PRF/5, HLE and HLF cells),
human breast cancer MCF-7 cells and human pancreatic cancer
AsPC-1 cells were cultured in Dulbecco’s modified Eagle’s or
RPMI1640 medium supplemented with 10% fetal calf serum.
Northern blot analysis
Total RNA (10mg) was isolated with Trizol (Life Technologies,
Rockville, MD, USA), subjected to electrophoresis in a denaturing
formaldehyde–agarose gel and transferred to a nylon filter. MK
(Kadomatsu et al, 1988) and AFP cDNA (Morinaga et al, 1983)
were labelled with [
32P]dCTP and used as probes. The hybridisa-
tion was performed in a solution of 50% formamide/5 SSC/
50mM NaH2PO4/2 Denhardt’s solution/0.1% SDS/0.1mgml
 1
salmon sperm DNA at 421C for 12h. The filter was washed with
a solution of 0.2 SSPE/0.1% SDS several times at 501C. The same
filter was rehybridised with a human 18S ribosome cDNA as a
control.
Dual luciferase assay
The 2335-bp genomic DNA fragment of the MK gene ( 2285/þ50,
þ1 corresponds to the transcription start site) (Uehara et al, 1992)
was cloned into the pGL2-basic vector (Promega, Madison, WI,
USA) that contained the firefly luciferase gene without any
promoter sequences (MK2.3-luc). MK2.3kb-luc DNA was digested
with XhoI/Eco47III to produce the 609-bp fragment-linked firefly
luciferase genes (MK0.6-luc). The AFP promoter region (AFP0.2,
212-bp SacI/HindIII fragment) and the enhancer (934-bp SwaI/
EcoRI fragment)-linked AFP promoter region (AFPEn0.2) were
prepared from pAF5.1-CAT (Nakabayashi et al, 1991), and they
were subcloned into pGL2-basic vector (AFP0.2-luc, AFPEn0.2-
luc). The transcriptional activity was measured with the dual
luciferase reporter assay system (Promega). Plasmid DNA contain-
ing respective genomic fragments, pGL2-control vector (Promega)
harbouring the SV40 promoter-linked firefly luciferase gene
(SV40-luc) or pGL2-basic, together with a control vector, the
renilla luciferase gene fused with the HSV-TK promoter (pRL-TK,
Promega) at a molar ratio of 10:1, was transfected into target cells
with a lipofectin reagent (Life Technologies, Gaithersburg, MD,
USA). After 2 days, cells were lysed and the luciferase activities
were measured according to the manufacturer’s protocol. The
relative firefly luciferase activity of each cell lysate was calculated
based on the amount of luminescence produced by renilla
luciferase and was expressed as a percentage of the SV40
promoter-mediated activity. All of the values were expressed as a
mean of four independent experiments. The statistical analysis was
performed by one-way analysis of variance (ANOVA).
In vitro sensitivity to ganciclovir
The 2.3kb. MK or the enhancer-linked AFP promoter region was
ligated into pcDNA3 vector (Invitrogen, San Diego, CA, USA) from
which the cytomegalovirus promoter was removed. The herpes
simplex virus-thymidine kinase (HSV-TK) gene was then cloned
into the downstream of the promoters (MK2.3-TK, AFPEn0.2-TK).
Cells were transfected with MK2.3-TK, AFPEn0.2-TK or pcDNA3
vector DNA and G418 (Life Technologies)-resistant cells were
selected. The pooled cells were seeded in 96-well plates at a density
of 5 10
3cellswell
 1 and were cultured with various concentra-
tions of ganciclovir (GCV). After 5 days, viable cells in each well
were measured with a cell-counting kit (Wako, Osaka, Japan). The
amount of formazan produced in each well was determined from
the absorbance at 450nm.
RESULTS
Expression of the MK and AFP genes in HCC
We examined the frequency of expressed MK and AFP genes in
paired HCC and noncancerous specimens of the same patients by
Northern blot analysis. In all, 14 out of 15 HCC specimens but
none of the corresponding noncancerous samples was positive for
MK mRNA expression. Three HCC specimens expressed the AFP
gene and one of the AFP-positive samples was also AFP-positive in
the corresponding noncancerous region (Table 1, Figure 1).
Frequency and tumour specificity of the expression in human
HCC was thus greater for the MK compared with the AFP gene.
Serum AFP values of the patients were not correlated with the
results of AFP mRNA expression.
Table 1 Expression of the MK and AFP genes in human HCC specimens
Pathology Expression
a
HCC Noncancerous MK AFP Serum AFP
b
No Age Gender HBs antigen HCV antibody (HCC/Noncancerous) (ngml
 1)
12 3 M +   mode, trab/pseud CH +/  +/+ 21
24 8 M +   mode, sci CH +/  +/  10892
35 2 M +   mode, trab CH +/   /  70
45 7 M   + mode, trab CH +/   /  23
56 1 M   + well, trab CH +/   /  15
66 6 M   + poor, com CH +/   /  5
76 8 M   + mode, trab CH +/   /  3
86 9 M +   mode, trab CH +/   /  26
97 3 M +   mode, trab CH +/   /  124
10 49 F +   mode, trab CH +/   /  3
11 52 F NA NA poor, com CH  /   /  41
12 58 F +   mode, trab CH +/  +/  1434
13 59 F   + well, trab CH +/   /  572
14 74 F   + mode, trab LC +/   /  2999
15 55 M   + well, trab LC +/   /  14
Abbreviations: M¼male, F¼female, NA¼not available, well¼well differentiated, mode¼moderately differentiated, poor¼poorly differentiated, trab¼trabecular type,
pseu¼pseudoglandular type, com¼compact type, sci¼scirrhous type, CH¼chronic hepatitis, LC¼liver cirrhosis.
aExpression of the MK and AFP genes in HCC and
noncancerous region of the same patients was examined with Northern blot analysis and was shown as positive (+) or negative ( ).
bSerum AFP before surgical operation.
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We investigated the transcriptional activity of MK and AFP
promoters with the luciferase reporter assay. Our previous studies
showed that a 2.3- or a 0.6-kb genomic fragment of the MK gene
contained cis-acting elements, which could activate an exogenous
gene preferentially in tumours (Miyauchi et al, 2001; Yoshida et al,
2002). Linkage of 0.2-kb AFP promoter and 0.9-kb AFP distal
enhancer gave the maximal transcription of a fused reporter gene
(Nakabayashi et al, 1991). We thereby examined the transcrip-
tional activity of four kinds of reporter constructs (MK2.3-luc,
MK0.6-luc, AFP0.2-luc and AFPEn0.2-luc) in AFP-producing
(HuH-7 and PLC/PRF/5) and -nonproducing (HLE and HLF)
HCC cell lines (Niwa et al, 1996; Ishikawa et al, 1999), and in non-
HCC cell lines (MCF-7 and AsPC-1), which were positive for MK
expression (Miyauchi et al, 2001).
Introduction of the respective reporter genes into HCC cell lines
revealed that transcriptional activity of the 2.3- or 0.6-kb MK
fragment was greater than that of the SV40 or the AFP promoter
(Po0.001, Figure 2). Since HuH-7 and PLC/PRF/5 cells are AFP-
high and AFP-intermediate producers, respectively (Niwa et al,
1996; Ishikawa et al, 1999), the transcriptional activity of the AFP
promoter was greater in HuH-7 than in PLC/PRF/5 cells. Addition
of AFP enhancer augmented the AFP promoter-mediated tran-
scriptional activation particularly in HuH-7 cells (Po0.001). The
luciferase activity of AFPEn0.2-luc DNA was then comparable to
that of the MK2.3-luc DNA in HuH-7 cells. In AFP-nonproducers,
however, the transcriptional activity of the AFP promoter or the
enhancer-linked AFP promoter was minimal.
The transcriptional activity of the 2.3- or 0.6-kb MK fragment
was comparable to that of the SV40 promoter in non-HCC cells as
previously reported (Miyauchi et al, 2001) and the AFP promoter
did not activate the fused luciferase gene in these cells.
In vitro sensitivity to GCV
We compared increased cytotoxic activity caused by the HSV-TK/
GCV system using the MK and the AFP promoters. All the cells
were transfected with MK2.3-TK, AFPEn0.2-TK or vector DNA and
then respective G418-resistant cells were exposed to various
concentrations of GCV (Figure 3). The sensitivity of vector DNA-
transfected cells was not different from that of respective parent
cells. However, AFP-producing HuH-7 and PLC/PRF/5 cells
increased the susceptibility to GCV, when they were transfected
AFP
MK
18S
Case 13 Case 2
HCC HCC Non
cancerous
Non
cancerous
Figure 1 Expression of the MK and AFP genes in human surgical
specimens was examined with Northern blot analysis. Representative
samples were shown and the expression of 18S ribosomal RNA gene was
used as controls.
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Figure 2 Transcriptional activity of the MK and AFP genomic fragments
tested in AFP-producing HCC (HuH-7 and PLC/PRF/5), AFP-nonproducing
HCC (HLE and HLF) and non-HCC (MCF-7 and AsPC-1) cells. The
relative firefly luciferase activity was expressed as a percentage of the SV40
promoter-mediated activity. Standard error bars are also shown.
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Figure 3 Susceptibility of HuH-7 (A), PLC/PRF/5 (B), HLE (C), HLF
(D), MCF-7 (E) and AsPC-1 (F) cells to various concentrations of GCV.
Parent cells and G418-resistant cells that were transfected with vector,
MK2.3-TK or AFPEn0.2-TK DNA were used. Standard error bars are also
shown.
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cells were more susceptible to GCV than HuH-7 cells, although the
transcriptional activity of both MK and AFP promoters was
stronger in HuH-7 than in PLC/PRF/5 cells. AFP-nonproducing
HCC and non-HCC cells that were transfected with MK2.3-TK
DNA significantly increased their susceptibility to GCV and those
transfected with AFPEn0.2-TK DNA also slightly increased the
susceptibility (Figure 3C–F). The increased sensitivity of the
AFPEn0.2-TK transfectants, despite minimal transcriptional activ-
ity of the AFPEn0.2 DNA in these cells, was probably due to
multiple integration of transfected DNA, in which condition
cellular and/or plasmid-derived promoters could activate the TK
gene.
DISCUSSION
In this study, we showed that human HCC specimens expressed
the MK gene more frequently than the AFP gene and that the
transcriptional activity of the MK promoter was as strong as that of
the enhancer-linked AFP promoter. The present data also indicate
that the MK promoter could activate the HSV-TK gene in HCC cells
to a similar extent as the AFP promoter. The AFP promoter has
been used to activate a suicide gene in HCC cell lines (Kanai et al,
1996; Mawatari et al, 1998), to produce a hybrid promoter in
combination with other regulatory regions (Ido et al, 2001) and to
apply to oncolytic adenovirus (Hallenbeck et al, 1999). These
previous studies suggested the feasibility of the AFP promoter-
mediated gene therapy for HCC. However, relatively low frequency
of AFP expression in human HCC may hamper the clinical
application. Although serum AFP was elevated in 70% of HCC
patients (Nakabayashi et al, 1991), AFP transcripts were not
frequently detected with Northern blot analysis as shown in the
present study. Di Biscegile et al. (1986) reported that nine out of 10
HCC patients showed elevated serum AFP values, but only two out
of the 10 HCC specimens were positive for the mRNA with
Northern blot analysis. Similar cases, high serum AFP values with
undetectable AFP transcript with Northern blot analysis, were also
reported (Varagona et al, 1992; Niwa et al, 1996), although the level
of AFP mRNA expression in general correlated with serum AFP
levels (Niwa et al, 1996). With more sensitive methods,
noncancerous samples as well as HCC specimens turned out to
be positive for AFP mRNA expression, since preneoplastic cells in
liver cirrhosis could produce AFP (Otsuru et al, 1988). These data
collectively raise the possibility that the AFP promoter may not
activate fused exogenous genes in some of serum AFP-positive
HCC cases. On the contrary, frequent expression of the MK gene
implies a possible strategy of MK promoter-based therapy for HCC
patients, although the expression is not specific to HCC.
The specificity of transcriptional activity by the MK and the AFP
promoter has been already demonstrated; both promoters could
drive the fused gene in respective MK- or AFP-positive cells but
not in MK- or AFP-negative cells (Kanai et al, 1996; Miyauchi et al,
2001). The mechanism of preferential expression of the MK gene in
tumours was not fully understood. It could be related with cell
growth: forced expression of MK in fibroblasts induced cell
transformation (Kadomatsu et al, 1997) and suppressed expression
of MK inhibited the tumour growth (Takei et al, 2001).
Recent studies demonstrated feasible application of tumour-
specific promoters to oncolytic adenovirus, which could replicate
within tumours but not in normal tissues (Heise and Kirn, 2000).
The MK promoter-mediated oncolytic adenovirus was not harmful
to liver but killed MK-positive tumours (Adachi et al, 2000). These
data suggested that MK promoter-based gene therapy could
facilitate selective killing of HCC and keep surrounding non-
cancerous tissues undamaged. The present Northern blot analysis,
in fact, implied that MK promoter-mediated gene therapy for
HCC would not injure surrounding cirrhosis tissues. Extracorporal
intratumoural injection technique could also broaden the applica-
tion of MK promoter-based therapy for HCC patients. Since
maintenance of residual liver functions is crucial for HCC
treatment, the MK promoter could provide an alternative
therapeutic approach besides AFP promoter-based therapy.
The present study suggested that the AFP promoter and the
MK promoter are applicable to AFP-high- and AFP-low/
nonproducing HCC, respectively, and the feasibility of both kinds
of the promoter-based therapy will be investigated in clinical
settings.
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